A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
about
Stathmin decreases cholangiocarcinoma cell line sensitivity to staurosporine-triggered apoptosis via the induction of ERK and Akt signaling.Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel diseaseNilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.
P2860
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A combination of sorafenib and ...... ate-resistant prostate cancer.
@ast
A combination of sorafenib and ...... ate-resistant prostate cancer.
@en
type
label
A combination of sorafenib and ...... ate-resistant prostate cancer.
@ast
A combination of sorafenib and ...... ate-resistant prostate cancer.
@en
prefLabel
A combination of sorafenib and ...... ate-resistant prostate cancer.
@ast
A combination of sorafenib and ...... ate-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
A combination of sorafenib and ...... rate-resistant prostate cancer
@en
P2093
Hayley Nehoff
Monica Archibald
Rhonda J Rosengren
Tara Pritchard
P2860
P304
P356
10.2147/IJN.S97286
P407
P577
2016-01-08T00:00:00Z